Hypogammaglobulinemia in Experimental Myeloma: the Role of Suppressor Factors from Mononuclear Phagocytes
Overview
Authors
Affiliations
We have investigated the pathogenesis of the polyclonal hypogammaglobulinemia associated with BALB/c plasmacytomas TEPC-183 and SPQC-11 to gain insight into the hypogammaglobulinemia observed in human myeloma. With pokeweed mitogen-driven IgM biosynthesis by mouse splenocytes as the indicator system for suppression, we found that a protein extract of asscites cells obtained from these tumor-bearing animals could suppress immunoglobulin production, whereas like extracts from a non-suppressing plasmacytoma, modified RPC-5, caused no suppression in vitro. Extracts of tumor ascites depleted of mononuclear phagocytes by iron carbonyl treatment showed little suppressor activity. The active extract was not cytotoxic and contained no mycoplasma or common murine viruses. Furthermore, the active suppressor factor appears to be a low m.w. protein that is not affected by treatment with ribonuclease. These results and others are consistent with the idea that the hypogammaglobulinemia of myeloma is due to the formation of immunoregulatory macrophage-like cells which synthesize a suppressor substance.
Joshua D, Humphrey J, Grennan D, Brown G Immunology. 1980; 40(2):223-8.
PMID: 7409859 PMC: 1458001.
The role of T, B and adherent cells in the in vitro immune response of TEPC-183-bearing mice.
Patel M, HAVAS H Immunology. 1982; 46(1):97-105.
PMID: 6978846 PMC: 1555334.
The mode of action of splenic suppressor cells in murine plasmacytoma.
Chen Y, Heller P Clin Exp Immunol. 1981; 45(3):514-22.
PMID: 6461449 PMC: 1537407.
Immunoregulatory T cell function in multiple myeloma.
Ozer H, Han T, HENDERSON E, Nussbaum A, Sheedy D J Clin Invest. 1981; 67(3):779-89.
PMID: 6451635 PMC: 370629. DOI: 10.1172/JCI110095.
Imbalances of T-cell subsets in monoclonal gammopathies.
Bergmann L, Mitrou P, WEBER K, Kelker W Cancer Immunol Immunother. 1984; 17(2):112-6.
PMID: 6331877 PMC: 11039025. DOI: 10.1007/BF00200046.